Week's news analysis

Adare Pharma Solutions acquires
Frontida BioPharm

By Editors - 06 December 2021

Adare Pharma Solutions acquiert Frontida BioPharm, Inc. a US-based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies.

Frontida supports pharmaceutical companies in the development, scale-up and commercial manufacturing of immediate and controlled-release oral solid dose, powder and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products. Frontida's Cat.One (Category One) Laboratory is a leader in the manufacturing of pain management products designed to prevent substance abuse.

the 325,000+ sq. ft. manufacturing facilities located in Philadelphia, PA and Aurora, IL offer a comprehensive suite of solutions for the development and commercialization of prescription, OTC, Highly Potent Active compounds, Phase I through Phase III clinical trial materials, Fixed-dose Combination products and DEA schedule II - V products. Frontida is equipped with multiple world-class commercial packaging lines, capable of validated product serialization, and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. Frontida has an annual capacity to manufacture up to 3 billion tablets and capsules.

The acquisition reinforces Adare's commitment to transform drug delivery by providing world class solutions from product development through commercial scale manufacturing and packaging. Adare's portfolio of offerings for its customers will expand to include new capabilities such as high potency compound handling and packaging services. The combination of the two organizations will further establish Adare as a leader in the development and manufacturing of life saving medications in complex dosage forms.

Together, the combined company will offer an expanded suite of solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and bioavailability enhancement. The addition of Frontida brings Adare's manufacturing footprint to seven sites globally and expands Adare's integrated, end-to-end offering to its partners. The combined organization will be led by Vivek Sharma.

In April 2020, Adare Pharmaceuticals, Inc., has acquired the pharmaceutical technology company, Orbis Biosciences, Inc. of Lenexa, KS.

Orbis provides enhanced technologies in a scaled, single-step manufacturing process. Its Precision Particle FabricationTM technology is the only technology currently on the market that can produce uniform particles in a size ranges suitable for use in injectable, otic and oral dosage forms. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins.

Adare is backed by private equity firms Thomas H. Lee Partners and Frazier Healthcare Partners. RBC Capital Markets, LLC acted as exclusive financial advisor to Adare for this transaction.

RELATED PCI Pharma Services has acquired LSNE

Go to Top